Captisol

Alectinib was synthesized by Chugai Pharmaceutical Co., Ltd. (Tokyo, Japan). Erlotinib was provided by F. Hoffmann-La Roche Ltd. (Basel, Switzerland). Infrigatinib (BGJ398), osimertinib, neratinib, and dabrafenib were obtained from LC Laboratories (Woburn, MA, USA). AZD4547 and trametinib were obtained from ChemScene (Monmouth Junction, NJ, USA). Lorlatinib, capmatinib, and lapatinib were obtained from Selleck Chemicals (Houston, TX, USA). The anti-cancer compound library was obtained from TargetMol (Boston, MA, USA). All agents were dissolved in dimethyl sulfoxide (DMSO: Sigma-Aldrich, St. Louis, MO, USA) for in vitro assays and in a 6% (w/v) solution of Captisol (ChemScene) for in vivo assays. DMSO and Captisol were used as vehicle controls. Recombinant human FGF1, FGF2, FGF7, and FGF12 proteins were obtained from R&D Systems (Minneapolis, MN, USA) and dissolved in phosphate-buffered saline (PBS, Sigma-Aldrich). Recombinant human FGF9 and FGF18 proteins were obtained from Abcam (Cambridge, UK) and dissolved in distilled water. Recombinant human FGF11 protein was obtained from LifeSpan Biosciences (Seattle, WA, USA) and dissolved in Tris buffer (Horizon Discovery, Cambridge, UK).

Osmotic pumps (ALZET, Cupertino, CA, USA) filled with temsirolimus solution (Pfizer, New York, NY, USA) were subcutaneously implanted into the mice. The Akt inhibitor MK-2206 (Active Biochemicals Co., Hong Kong) was dissolved in 30% captisol (ChemScene, Monmouth Junction, NJ, USA) and orally administered. Control mice were administered the vehicle.